References:

1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466.
2. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared Dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR activating mutations. J Clin Oncol. 2018;3 6(22):2244-2250.
3. Local Prescribing Document for DACOPLICE®. LPD Version 3. Pfizer India_LPDDAC012020.

Please click on Prescribing Information link to view safety and adverse events information of DACOPLICE®